UK grants marketing authorisation to “landmark” breast cancer therapy
Seagen's Tukysa® (tucatinib) was approved in the UK as part…
Seagen's Tukysa® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.